Ways to help
About us
Contact Us
Feb 2017
Trish Foundation contributes to first-ever discovery
Jun 2017
Researchers funded by the Trish Foundation making great progress
Dec 2017
Announcement by NHMRC
Jan 2018
2018 Round of Funding Four new Projects announced
Jun 2018
Exciting regrowth of nerve fibres
Jun 2018
Dr Merson secures $1 million from NHMRC
Jun 2018
Findings submitted for publication
Jan 2019
New Research Projects commencing 2019 announced

Studying MS susceptibility genes

to understand the role of EBV in MS

Dr Fiona McKay, from The Westmead Institute for Medical Research in Sydney, was awarded an MS Research Australia Incubator grant in 2015.

Funded by the Trish MS Research Foundation, to support her work studying how MS risk genes may change the way the immune system responds to the Epstein-Barr virus (EBV) and how this might increase vulnerability to MS. Previous infection with Epstein-Barr virus (EBV) is known to be a significant risk factors for MS.

Dr McKay conducted experiments to identify how four key MS susceptibility genes play a role in immune cells involved in the EBV infection pathway, and how this interaction may contribute to the onset of MS.

In order to test this, Dr McKay used DNA and immune cells collected from individuals with MS and people without MS to examine how these MS risk genes could be affecting the control or response to EBV infection. 

This project has been extremely successful and achieved a number of important outcomes during the one-year grant. Dr McKay and colleagues found that three key MS risk genes were associated with increased evidence of EBV antibodies in the blood (a sign of higher EBV activity). They also found that the presence of the MS risks genes was associated with lower activity of other genes in the immune cells that fight EBV infection.

Dr McKay also successfully infected B immune cells grown in the laboratory with EBV and is currently investigating how EBV affects the structure and function of the B cells. Following on from this project, Dr McKay will define the effect of these risk genes on the ability of the immune system to kill EBV-infected immune cells.

These findings provide further support for the idea that genetic variations may underpin how an individual responds to EBV infection and supports the growing evidence that people with MS have a reduced response to EBV infection that leaves them vulnerable to developing MS. This research complements the research that Professor Michael Pender at the University of Queensland, also supported by MS Research Australia and the Trish MS Research Foundation, has been conducting over many years. His work also reveals that people with MS have a deficiency in the sub-type of immune cells that help respond to EBV infection. Dr McKay’s work helps fill in some of the detail of the mechanisms by which that might occur.

Dr McKay and her team have already published two scientific manuscripts on their findings and have used the results from these pilot studies to underpin a number of large grant applications to continue this research. Ultimately this research will help narrow down the immune cell types and the biological pathways that can be targeted to help address the imbalance in the immune system, clear EBV infection and more effectively treat MS.

Trish Foundation & MS Research Australia Working together to find a cure for MS
Copyright © Trish Multiple Sclerosis Research Foundation. All rights reserved.